Overview In line with grant requirements, the C-SiG Pilot and Feasibility (P/F) Program: 1) Supports both new investigators just beginning their careers in digestive diseases research or innovative research proposals from experienced investigators who plan to change their area of research;ii) Provides investigators with vital funds to obtain preliminary data that support research grant applications from external agencies, especially NIH ROl grant submissions;and, iii) Provides mentorship, critical review of proposals, and coaching to improve the competitiveness of grant applications. We are strongly focused on junior investigators and Mayo Clinic has a sustained and rich tradition of facilitating the transition of junior investigators to independent scientists. As of February 2013, there were 1932 fellows (1311 MD (or equivalent), 130 MD/PhD, and 491 PhD) and 113 research trainees at Mayo Clinic Rochester. The Division of Gastroenterology and Hepatology (GIH) had a total of 82 fellows (36 fellows in the clinical training program, 5 fellows on our longstanding NIH Gl training grant, 41 postdoctoral research fellows) and 15 research trainees. GIH junior investigators comprise 26% of P/F applicants and 46% of the awardees. The C-SiG P/F Program works closely with the GIH Division and other Departments and Centers to help junior investigators achieve independent funding and to bring experienced investigators with C-SiG-relevant expertise into digestive disease research.

National Institute of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Center Core Grants (P30)
Project #
Application #
Study Section
Special Emphasis Panel (ZDK1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Mayo Clinic, Rochester
United States
Zip Code
Ni, Jun; Wangensteen, Kirk J; Nelsen, David et al. (2016) Active recombinant Tol2 transposase for gene transfer and gene discovery applications. Mob DNA 7:6
Landry, Greg M; Hirata, Taku; Anderson, Jacob B et al. (2016) Sulfate and thiosulfate inhibit oxalate transport via a dPrestin (Slc26a6)-dependent mechanism in an insect model of calcium oxalate nephrolithiasis. Am J Physiol Renal Physiol 310:F152-9
Ma, Alvin C; McNulty, Melissa S; Poshusta, Tanya L et al. (2016) FusX: A Rapid One-Step Transcription Activator-Like Effector Assembly System for Genome Science. Hum Gene Ther 27:451-63
Khanna, S; Montassier, E; Schmidt, B et al. (2016) Gut microbiome predictors of treatment response and recurrence in primary Clostridium difficile infection. Aliment Pharmacol Ther 44:715-27
Druliner, Brooke R; Rashtak, Shahrooz; Ruan, Xiaoyang et al. (2016) Colorectal Cancer with Residual Polyp of Origin: A Model of Malignant Transformation. Transl Oncol 9:280-6
Tomita, Kyoko; Freeman, Brittany L; Bronk, Steven F et al. (2016) CXCL10-Mediates Macrophage, but not Other Innate Immune Cells-Associated Inflammation in Murine Nonalcoholic Steatohepatitis. Sci Rep 6:28786
Kawakami, Hisato; Huang, Shengbing; Pal, Krishnendu et al. (2016) Mutant BRAF Upregulates MCL-1 to Confer Apoptosis Resistance that Is Reversed by MCL-1 Antagonism and Cobimetinib in Colorectal Cancer. Mol Cancer Ther 15:3015-3027
Tabibian, James H; Varghese, Cyril; LaRusso, Nicholas F et al. (2016) The enteric microbiome in hepatobiliary health and disease. Liver Int 36:480-7
Verma, Vikas K; Li, Haiyang; Wang, Ruisi et al. (2016) Alcohol stimulates macrophage activation through caspase-dependent hepatocyte derived release of CD40L containing extracellular vesicles. J Hepatol 64:651-60
Ding, Xiwei; Chaiteerakij, Roongruedee; Moser, Catherine D et al. (2016) Antitumor effect of the novel sphingosine kinase 2 inhibitor ABC294640 is enhanced by inhibition of autophagy and by sorafenib in human cholangiocarcinoma cells. Oncotarget 7:20080-92

Showing the most recent 10 out of 399 publications